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of pan-resistant Acinetobacter spp or carbapenem-resistant
Klebsiella spp (e.g. roommates of newly identiﬁed carriers)
and apply speciﬁc preventive measures (contact isolation)
applied to identiﬁed carriers, especially in the critical
care setting. Second, eradicating carriage of multi-resistant
bacteria may reduce the rates of infection. However, no con-
trolled studies are available indicating that this approach
may work. Third, strict compliance with standard pre-
cautions and hand hygiene could prevent most cases of
cross-transmission, even without the need for recognition
of individual carriers of resistant microorganisms. Unfor-
tunately, many studies have shown that compliance of
healthcare workers with hand hygiene recommendations
remains low. Implementing alcohol-based hand rinses can
improve compliance and decrease cross-infection. Finally,
antibiotic selection pressure contributes to the increase in
prevalence of multi-resistant Gram-negative bacteria. Data
from several recently published studies suggest that restric-
tion of certain classes of antibiotics may decrease rates
of multi-resistant Gram-negative bacteria in the hospital
setting. Other well-designed investigations are needed to
conﬁrm that reduction in antimicrobial overuse has a favor-
able effect on infection rates caused by multi-resistant
Gram-negative bacteria.
doi:10.1016/j.ijid.2008.05.062
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Burden of Pertussis Worldwide: Strategies to Reinforce
Pertussis Control in Children, Adolescents, and Adults
K. Forsyth
Flinders Medical Centre and Flinders University, Adelaide,
Australia
Pertussis disease is a signiﬁcant cause of morbidity and
mortality amongst the unimmunised or insufﬁciently immu-
nised. Data on pertussis disease trends will be presented.
As for solutions, in spite of immunisation campaigns tar-
geted at parents of infants and children, there are still
major problems with. Strategies to reduce the burden of
pertussis disease include; universal adult immunisation,
selective immunisation of mothers and close family contacts
of newborns, selectiveimmunisation of health care work-
ers, selective immunisation of child care workers, universal
immunisation of adolescents, pre-school boosters at 4—6
years of. No single strategy is likely to be appropriate for
all. Data on pertussis disease and discussion around these
public health policy issues for the prevention of pertussis
will be discussed.
doi:10.1016/j.ijid.2008.05.063
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ertussis Control in Infants and Children
. Thisyakorn
Chulalongkorn Hospital, Bangkok, Thailand
n the prevaccine era, pertussis was one of the most com-
on childhood bacterial infections with more than half of
hildren becoming infected before school age. The disease
as one of the leading causes of infant death in the 19th
entury.
The introduction of whole-cell pertussis vaccine in
he 1940s and its subsequent widespread use globally
as resulted in a reduction in the incidence, morbidity
nd mortality of this disease. The whole-cell pertussis
accine was nevertheless associated with frequent local
nd systemic adverse reactions, occasionally some that
ere more severe such as febrile seizures or hypotonic-
yporesponsive episodes. The shift, in the 1990s, from
hole-cell pertussis vaccine to less reactogenic acellular
ertussis vaccine was associated with signiﬁcantly reduced
ates of vaccine-associated adverse events. In recent years,
cellular pertussis vaccine has been incorporated into
he immunization schedules of many developed countries,
radually replacing whole-cell pertussis vaccine. Dosing
chedules vary between countries. As it has become appar-
nt that the epidemiology of pertussis is gradually shifting
o the adolescent and adult age groups, many countries are
ugmenting their program of immunization by having intro-
uced, or are planning to introduce, an acellular pertussis
accine booster dose for use in children 6 years of age or in
he adolescent age group.
The use of combination vaccines with inclusion of acel-
ular pertussis vaccine in many countries has been proven
o be efﬁcacious and prevents children from undergoing an
xcessive number of injections. The individual components
ncluded in these combination vaccines can be adjusted
ccording to differences in the burden of disease in different
ountries.
oi:10.1016/j.ijid.2008.05.064
0.003
he Role of Pertussis Booster Vaccinations in Adolescents
nd Adults
. Johnson
Sanoﬁ Pasteur, USA
n most developed countries, long-standing vaccination
rograms for infants and young children have led to substan-
ial decreases in pertussis disease since their introduction
n the 1940s. More recently, however, there has been a
esurgence of pertussis case reports, most notably among
dolescents and adults. Immunity from childhood pertus-
is vaccinations wanes after several years, but natural
oosting through repeated subclinical infection is now
ncommon; most adolescents and adults are again suscep-
ible to pertussis. Manifestations of pertussis in these age
roups are highly variable, ranging from mild symptoms
nlikely to prompt medical care through typical whoop-
ng cough. Complications are common and include sleep
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eprivation, school and work disruptions, rib fractures, and
neumonia.
Adolescents and adults not only experience substantial
orbidity and complications from pertussis, they play an
mportant role in transmission of Bordetella pertussis to
hildren. Multiple studies have documented that parents and
ther family members are the main source of pertussis infec-
ion in infants. Of particular concern are very young infants,
ho are at greatest risk for hospitalization and mortality
rom pertussis, and who are either incompletely vaccinated
r unvaccinated.
To address these concerns, adolescent/adult-formulation
etanus-diphtheria-acellular pertussis (Tdap) vaccines,
ometimes combined with injectable polio vaccine, have
een developed. These Tdap vaccines have been shown
n clinical trials to be safe and at least as immunogenic
gainst pertussis as their analogous pediatric vaccines. In
anada and the US, Tdap vaccination is recommended for
ll adolescents and adults < 64 years of age. Emphasis is
laced on vaccinating young adolescents and on vaccinating
dults (eg, new parents, child-care workers, and certain
ealthcare-personnel) who have close contact with infants.
anadian experience suggests that Tdap vaccine usage has
ontributed to further decreases in pertussis. Full control
f this disease, however, may require decennial boosting
ith Tdap vaccine, which is currently under study.
oi:10.1016/j.ijid.2008.05.065
ew Perspectives on Vaccine-preventable Diseases in
dults: Pneumococcal Disease and Herpes Zoster (invited)
1.001
pening Remarks - Adult Immunisation: Some Thoughts
. Hanna
Communicable Disease Control, Tropical Population Health
nit Network, Queensland Health, Cairns, Australia
dult immunisation can be categorised in several ways:-
mmunisation for travel - immunisation for certain occupa-
ions (eg. health-care and child-care workers)- immunisation
or those with certain medical conditions (eg. asplenia), -
mmunisation for the elderly.
Immunisation for the elderly, in particular, is gaining
reater recognition and greater credibility. Ageing pop-
lations, the increasing prevalence of certain medical
onditions in the aged, and a desire to keep the aged in opti-
al health, all have contributed to this recognition of the
eed for vaccines for, and for the delivery of these vaccines
o, the aged.
However, this greater recognition of the need has not
et been matched by greater uptake of vaccines by the
lderly, even in afﬂuent industrialised countries. For exam-
le, uptake of the annual inﬂuenza vaccine in those aged
65 years in the United States increased from 33% to 66% in
he 1990s, but has not increased since. Other countries do
ot even have mechanisms in place to determine the cov-
rage of vaccines in the elderly; in Australia, for example,
lthough inﬂuenza and pneumococcal polysaccharide vac-
ines are provided free to those aged ≥65 years, there is not
et a mechanism to determine uptake of these vaccines.
l
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Perhaps the main reasons for this disconnection between
ntent and outcome are that ‘‘adult immunisation is not yet
n essential element within the culture of adult medicine
or is it a health care priority in the minds of the public’’.
his suggests that increasing demand for adult immunisation
y improving professional and public awareness should be
iven greater priority; indeed this need for greater aware-
ess has been given priority in a recent policy statement on
dult immunisation from the Infectious Diseases Society of
merica.
oi:10.1016/j.ijid.2008.05.066
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Vaccine for the Prevention of Herpes Zoster and Its
omplications
. Levin
University of Colorado School of Medicine, Denver, CO, USA
aricella (chickenpox) is associated with a viremia that
esults in a life-long association of the varicella-zoster virus
VZV) with neurons in sensory ganglia. VZV remains in a clin-
cally inapparent (latent) form in these neurons because of
he presence of VZV-speciﬁc immune responses that appear
t the time of the childhood varicella infection. However,
hen these responses decline, as occurs with immune sup-
ression, the latent VZV reactivates and causes herpes
oster (HZ). These same protective responses also decline
aturally as part of the aging process. This explains why
Z occurs in approximately one-quarter of all people in
heir lifetime; 20% of cases occur in those who are 50—59
ears old and 60% occur in older people (incidence is 1/100
ersons per year for those ≥60 years). Not only does the
ncidence of HZ increase with aging, but the duration and
everity of this painful disease increases with aging, as
oes its main complication - prolonged pain (post-herpetic
euralgia; PHN). Since HZ is the consequence of declining
ZV-speciﬁc immunity, it was suggested that boosting this
mmunity in older people would prevent HZ and/or lessen
ts severity. A double-blinded, placebo-controlled, trial of a
ive, attenuated, HZ vaccine has proven this hypothesis to
e correct. The HZ vaccine reduced the frequency of HZ (by
0%) and it reduced the pain and suffering (including PHN) by
65%, and as a consequence, is recommended in the United
tates for routine use in people ≥60 years of age. The details
f the clinical trial and potential issues raised by its use will
e discussed.
oi:10.1016/j.ijid.2008.05.067
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erpes Zoster and Post Herpetic Neuralgia (PHN) - The
aiwan Perspective
.C. Yang
Department of Neurology, National Taiwan University, Col-
ege of Medicine, Taipei, Taiwan
he objective of this study is to estimate the incidence of
Z among the Taiwanese population, and investigate the
isease burden of HZ by analyzing the utilization of health
